drugset / Trial / NCT02500810
Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients
Phase 2
Unknown
106 enrolled
Peking University Cancer Hospital & Institute
Beijing Shijitan Hospital, Capital Medical University · collabCancer Institute and Hospital, Chinese Academy of Medical Sciences · collabChinese PLA General Hospital · collabPeking Union Medical College Hospital · collabPeking University First Hospital · collabPeking University Third Hospital · collabWeifang People's Hospital · collabYantai Yuhuangding Hospital · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to determine whether monosialoganglioside are effective in the prevention of neurotoxicity induced by albumin-bound paclitaxel chemotherapy in lung cancer patients, and improve the quality of life of patients.
Timeline
- Start
- 2015-07
- Primary completion
- 2018-07
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Monosialoganglioside | Unknown | 40 mg | Intravenous |